P2‐131: analysis of a family with identical triplets discordant for alzheimer's disease

Ming Zhang,Allison Ann Dilliott,John Robinson,Rob Hegele,Michael Comishen,Christine Sato,Richard Mayeux,Peter St George-Hyslop,Morris Freedman,Ekaterina Rogaeva

DOI: https://doi.org/10.1016/j.jalz.2018.06.817

2006-01-01

Alzheimer s & Dementia

Abstract:Genetics is now commonly used in the diagnosis of Alzheimer's disease (AD); however, age of onset in AD patients is highly variable (e.g., 39-85 years in carriers of APP mutations), suggesting the action of genetic or epigenetic modifiers. Monozygotic (MZ) twins/triplets provide a unique opportunity to investigate risk/protective factors in disease development. We studied a unique Ashkenazi Jewish family with AD-discordant MZ triplets recruited from Baycrest Health Sciences in Toronto. Genetic and epigenetic analyses were conducted on blood gDNA of five family members (the triplets, plus one affected and one unaffected offspring). We used a custom next-generation-sequencing-based panel developed by the Ontario Neurodegenerative Disease Research Initiative (ONDRISeq) that targets 80 genes associated with neurodegeneration, as well as a genome-wide Neuro-X array evaluating ∼264,000 mainly coding variants (Polyphen-2 and MutationTaster were used to select potentially damaging rare variants). In addition, we used the genome-wide Infinium MethylationEPIC chip, which provides DNA methylation levels for 850,000 CpG and CHH (H correspond to A, T or C) sites. The monozygosity of the triplets was confirmed by the identical genotypes of all investigated genetic markers. Two of the triplets developed AD at age 76 and 73 years, while the third remains free from dementia at age 83 years. The offspring of one of the affected triplets developed early onset AD at age 50. All family members have normal C9orf72 repeat length (<8 repeats). The triplets and AD affected offspring are carriers of the AD risk APOE e4-allele. In addition, ONDRIseq identified eight potentially damaging rare variants, including missense substitutions in SORL1 (p.W1563C) and APP (p.S198P). Results of the ongoing analysis of family members on the Neuro-X and MethylationEPIC arrays will be presented. The APOE e4-allele together with some rare missense variants (e.g., in SORL1) may contribute to the AD risk in the investigated family. However, genetic factors could not explain the discordance for AD in the triplets, which may be linked to epigenetic events, e.g. DNA methylation, triggered by environmental factors or ageing. We will clarify if acceleration of DNA methylation age is increased in family members affected by an earlier age at onset.